Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX1 | P51575 | 7/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 10/20 | 0.49 |
| ▸ | JUN | P05412 | 9/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 9/20 | 0.49 |
| ▸ | RELA | Q04206 | 9/20 | 0.49 |
| ▸ | XPO1 | O14980 | 2/20 | 0.49 |
| ▸ | TMPRSS4 | Q9NRS4 | 6/20 | 0.47 |
| ▸ | P2RX4 | Q99571 | 4/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | IKBKB | O14920 | 1/20 | 0.47 |
| ▸ | CHUK | O15111 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MYLK | Q15746 | 1/20 | 0.47 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.47 |
| ▸ | ATF1 | P18846 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL330789 | 0.86 | P2RX1 (0.64) | P2RX1NFKB1JUNNFKB2RELA | |
| SCHEMBL330263 | 0.78 | P2RX1 (0.78) | P2RX1TMPRSS4P2RX4P2RX7MEN1 | |
| SCHEMBL24823427 | 0.77 | P2RX1 (0.66) | P2RX1NFKB1TMPRSS4P2RX4P2RX7 | |
| SCHEMBL5423454 | 0.76 | RAB9A (0.57) | P2RX1TMPRSS4P2RX4P2RX7KMT2A | |
| SCHEMBL330211 | 0.72 | TRPV1 (0.59) | TMPRSS4MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL330156 | 0.70 | NR1H4 (0.60) | P2RX1TMPRSS4P2RX4P2RX7MEN1 | |
| SCHEMBL9118381 | 0.69 | ALDH1A1 (0.52) | NFKB1JUNNFKB2RELAMEN1 | |
| SCHEMBL330257 | 0.68 | P2RX1 (0.77) | P2RX1NFKB1NFKB2RELATMPRSS4 | |
| SCHEMBL329752 | 0.67 | CA1 (0.48) | SMN1; SMN2 | |
| SCHEMBL330392 | 0.67 | TMPRSS4 (0.75) | P2RX1TMPRSS4P2RX4P2RX7MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263657-B2 | Blocking neurokinins; using a benzene compound containing hydroxy or acetoxy group; antiinflammatory agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-09-11 | — | — | US | disclosed |
| US-8097759-B2 | Inflammatory cytokine release inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20100274051-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2010-10-28 | — | — | US | disclosed |
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20080249071-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-10-09 | — | — | US | disclosed |
| EP-1847263-A2 | Inhibitors against the production and release of inflammatory cytokines | Institute of Medicinal Molecular Design, Inc. (JP) | 2007-10-24 | — | — | EP | disclosed |
| EP-1844766-A2 | Inhibitors against the production and release of inflammatory cytokines | Institute of Medicinal Molecular Design, Inc. (JP) | 2007-10-17 | — | — | EP | disclosed |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1352650-A1 | INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES | Institute of Medicinal Molecular Design, Inc. (JP) | 2003-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100274051-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | P2RX1 1459/4885NFKB1 8/4885JUN 244/4885 |
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | P2RX1 1538/4885NFKB1 8/4885JUN 262/4885 |
| US-20080249071-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | P2RX1 1538/4885NFKB1 8/4885JUN 262/4885 |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | NFKBIA, IL1B, IKBKB | P2RX1 2316/4885NFKB1 6/4885JUN 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.